SCHEMBL829646

SCHEMBL829646

Cc1ccc2cc(OC(=O)N3CCCCC3)ccc2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.68
MAPT P10636 4/20 0.68
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
HTT P42858 2/20 0.68
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
LMNA P02545 2/20 0.61
ATM Q13315 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ALDH1A1 P00352 3/20 0.56
POLB P06746 1/20 0.56
TSHR P16473 3/20 0.50
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 1/20 0.47
SCN9A Q15858 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828658 0.99 SMN1; SMN2 (0.65) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL830461 0.88 SMN1; SMN2 (0.51) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL829344 0.86 GAA (0.54) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL833986 0.83 FAAH (0.54) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL830348 0.81 RAB9A (0.44) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL829423 0.81 NPC1 (0.47) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL829224 0.80 ACHE (0.48) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL829844 0.79 MGLL (0.57) SMN1; SMN2MEN1KMT2ANPC1L3MBTL1
SCHEMBL830176 0.79 SMN1; SMN2 (0.88) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL424926 0.77 PDE3B (0.52) SMN1; SMN2MAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 SMN1; SMN2 4842/4885MAPT 3311/4885MEN1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.